A detailed history of Charles Schwab Investment Management Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 715,597 shares of VKTX stock, worth $30.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
715,597
Previous 671,475 6.57%
Holding current value
$30.3 Million
Previous $35.6 Million 27.28%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$49.84 - $70.47 $2.2 Million - $3.11 Million
44,122 Added 6.57%
715,597 $45.3 Million
Q2 2024

Aug 12, 2024

SELL
$47.39 - $80.2 $7.94 Million - $13.4 Million
-167,509 Reduced 19.97%
671,475 $35.6 Million
Q1 2024

May 08, 2024

BUY
$17.4 - $94.5 $1.1 Million - $5.98 Million
63,285 Added 8.16%
838,984 $68.8 Million
Q4 2023

Feb 06, 2024

BUY
$9.24 - $19.64 $95,901 - $203,843
10,379 Added 1.36%
775,699 $14.4 Million
Q3 2023

Nov 08, 2023

BUY
$10.92 - $16.0 $5.52 Million - $8.09 Million
505,578 Added 194.65%
765,320 $8.47 Million
Q2 2023

Aug 09, 2023

BUY
$14.84 - $24.79 $3.31 Million - $5.53 Million
223,074 Added 608.36%
259,742 $4.21 Million
Q1 2023

May 11, 2023

BUY
$8.08 - $17.33 $62,232 - $133,475
7,702 Added 26.59%
36,668 $610,000
Q3 2022

Nov 14, 2022

SELL
$2.55 - $3.89 $39,525 - $60,295
-15,500 Reduced 34.86%
28,966 $79,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $3.15 $320,601 - $478,623
-151,944 Reduced 77.36%
44,466 $129,000
Q1 2022

May 13, 2022

BUY
$3.0 - $4.88 $57,252 - $93,129
19,084 Added 10.76%
196,410 $590,000
Q4 2021

Feb 11, 2022

BUY
$4.6 - $6.72 $24,062 - $35,152
5,231 Added 3.04%
177,326 $816,000
Q3 2021

Nov 16, 2021

BUY
$5.58 - $7.04 $3,102 - $3,914
556 Added 0.32%
172,095 $1.08 Million
Q2 2021

Aug 16, 2021

BUY
$5.19 - $6.73 $26,385 - $34,215
5,084 Added 3.05%
171,539 $1.03 Million
Q1 2021

May 17, 2021

BUY
$5.74 - $9.67 $65,275 - $109,967
11,372 Added 7.33%
166,455 $1.05 Million
Q4 2020

Feb 16, 2021

SELL
$5.3 - $6.71 $1,399 - $1,771
-264 Reduced 0.17%
155,083 $874,000
Q3 2020

Nov 13, 2020

SELL
$5.73 - $8.11 $35,130 - $49,722
-6,131 Reduced 3.8%
155,347 $905,000
Q2 2020

Aug 14, 2020

SELL
$4.35 - $8.08 $29,036 - $53,934
-6,675 Reduced 3.97%
161,478 $1.17 Million
Q1 2020

May 15, 2020

BUY
$3.45 - $7.95 $11,050 - $25,463
3,203 Added 1.94%
168,153 $787,000
Q4 2019

Feb 07, 2020

BUY
$6.38 - $8.73 $16,473 - $22,540
2,582 Added 1.59%
164,950 $1.32 Million
Q3 2019

Nov 08, 2019

BUY
$6.55 - $8.6 $91,837 - $120,580
14,021 Added 9.45%
162,368 $1.12 Million
Q2 2019

Aug 09, 2019

BUY
$7.67 - $10.63 $105,017 - $145,545
13,692 Added 10.17%
148,347 $1.23 Million
Q1 2019

May 14, 2019

BUY
$7.58 - $9.94 $41,485 - $54,401
5,473 Added 4.24%
134,655 $1.34 Million
Q4 2018

Feb 14, 2019

BUY
$7.16 - $16.21 $127,448 - $288,538
17,800 Added 15.98%
129,182 $989,000
Q3 2018

Nov 13, 2018

BUY
$9.7 - $19.65 $187,035 - $378,891
19,282 Added 20.94%
111,382 $1.94 Million
Q2 2018

Aug 08, 2018

BUY
$3.88 - $12.74 $357,348 - $1.17 Million
92,100 New
92,100 $875,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.